Storm Therapeutics Raises $56 Million in Series C Funding
Storm Therapeutics, a Cambridge, United Kingdom-based company specializing in RNA modification therapies for cancer, has successfully secured $56 million in its Series C funding round. The round saw participation from notable investors including M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, UTokyo Innovation Platform Co., Ltd. (UTokyo IPC), and Fast Track Initiative (FTI).
Company Overview
Storm Therapeutics focuses on developing novel cancer therapies by targeting RNA modifications. With a commitment to advancing cancer treatment, the company is led by Jerry McMahon, who serves as CEO and President.
Use of Funds
The $56 million raised will primarily be used to advance the development of STC-15, a pioneering METTL3 inhibitor. This small-molecule therapy is designed to reprogram malignant progenitor cells by altering mRNA methylation, a process crucial in the development of sarcomas and other cancers.
Clinical Advancement of STC-15
The funds will support a Phase 2 monotherapy study of STC-15 in selected sarcoma indications. Notably, the first patient has already been dosed in this trial. The study aims to establish a potential accelerated regulatory approval pathway for STC-15 and lay the groundwork for further clinical development across various oncology indications.
Investor Participation
While the Series C round did not have a lead investor, it attracted significant interest from a diverse group of investors. M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, UTokyo IPC, and Fast Track Initiative (FTI) have all contributed to this funding round, reflecting confidence in Storm Therapeutics' innovative approach to cancer treatment.
Future Prospects
With this substantial financial backing, Storm Therapeutics is well-positioned to push forward with its clinical trials and explore the full therapeutic potential of STC-15. The company's focus on RNA modifications represents a promising frontier in oncology, offering hope for more effective cancer treatments in the future.
As the company advances its research and development, the biotech industry and oncology community will be closely watching the outcomes of the ongoing trials and potential breakthroughs in cancer therapy.